Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 463,100 shares, an increase of 483.2% from the January 31st total of 79,400 shares. Approximately 8.0% of the shares of the company are short sold. Based on an average trading volume of 2,290,000 shares, the short-interest ratio is presently 0.2 days.
Bio-Path Stock Down 2.8 %
Shares of NASDAQ:BPTH opened at $0.18 on Friday. Bio-Path has a fifty-two week low of $0.12 and a fifty-two week high of $7.67. The firm has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $0.90.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on shares of Bio-Path in a report on Saturday, February 22nd. They issued a “sell” rating for the company.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- Retail Stocks Investing, Explained
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 5 Best Gold ETFs for March to Curb Recession Fears
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
